JP MORGAN/CALL/ELI LILLY & CO/920/0.1/21.06.24 Stock

Warrant

DE000JB4NTX4

Market Closed - Börse Stuttgart 03:38:35 2024-06-18 am EDT
0.11 EUR -31.25% Intraday chart for JP MORGAN/CALL/ELI LILLY & CO/920/0.1/21.06.24
Current month-38.89%
1 month+14.58%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-18 0.11 -31.25%
24-06-17 0.16 -46.67%
24-06-14 0.3 +36.36%
24-06-13 0.22 -21.43%
24-06-12 0.28 +27.27%

Delayed Quote Börse Stuttgart

Last update June 18, 2024 at 03:38 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
Issuer J.P. Morgan
WKN JB4NTX
ISINDE000JB4NTX4
Date issued 2023-10-18
Strike 920 $
Maturity 2024-06-21 (3 Days)
Parity 10 : 1
Emission price 0.79
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.16
Lowest since issue 0.075
Delta0x
Omega 0.000000
Premium0x
Gearing0x
Moneyness 0.9690
Difference Strike 28.54 $
Difference Strike %+3.10%
Intrinsic value 0.000000

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5 USD
Average target price
855.4 USD
Spread / Average Target
-4.05%
Consensus